Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
8:59pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.15
Open
$4.15
Day's High
$4.20
Day's Low
$4.12
Volume
38,662
Avg. Vol
89,777
52-wk High
$6.45
52-wk Low
$3.00

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.45
Market Cap(Mil.): $165.38
Shares Outstanding(Mil.): 31.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

06 Dec 2017

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

29 Nov 2017

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,364.40 +9.20

Earnings vs. Estimates